As emerging and re-emerging pathogens continue to challenge public health systems, this collection highlights critical developments across virology, vaccine innovation, and clinical research.
Download the eBook
The Infectious Disease Industry Focus eBook, sponsored by Sino Biological, takes a look at the latest scientific advances shaping the global response to infectious diseases.
Topics span high-impact threats such as Nipah virus, zoonotic transmission risks from influenza D and canine coronavirus, and the potential role of rat hepatitis E virus in human disease.
The book also explores major progress in vaccine development, including advances in RSV research, novel arbovirus vaccine designs aimed at improving safety, and DNA-based scaffolds to enhance immune targeting in HIV.
Alongside prevention strategies, Infectious Disease addresses ongoing global challenges such as the resurgence of measles despite reduced mortality, and new insights into the neurological consequences of severe COVID-19. Further discussion expands on today's therapeutic innovations, reviewing promising developments in simplified malaria treatment approaches demonstrating high clinical efficacy.
Together, this eBook provides scientists and researchers with a focused snapshot of the innovations and challenges defining infectious disease research today, emphasizing the critical role of continued scientific advancement in improving global health outcomes.
Download the eBook
About Sino Biological Inc.
Founded in 2007, Sino Biological is a global biotechnology company specializing in high-quality recombinant proteins, antibodies, and CRO services. Serving researchers in over 90 countries, Sino Biological supports basic research, drug discovery, vaccine development, and diagnostics through its comprehensive product portfolio, proprietary quality systems, and innovative research platforms.
Sino Biological's core business
Sino Biological is a leading global biotechnology supplier dedicated to high-quality research reagents and comprehensive CRO services. Its extensive product portfolio covers over 9,800 recombinant proteins, 15,000 antibodies, and 50,000 genes, all produced in-house. As a trusted CRO partner, Sino Biological specializes in customized recombinant protein and antibody production. It stands out with its robust high-throughput antibody production system including HEK293/CHO and cell‑free platforms. This system enables rapid turnaround (as fast as 5 days), high-throughput production (>10,000 Abs/month) and cost-effective solutions for global academic and pharmaceutical clients.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices, and treatments.